Bioreductive therapies: An overview of drugs and their mechanisms of action

International Journal of Radiation Oncology Biology Physics

Volumn 42, Issue 4, 1998, Pages 755-762

  Rauth, A M ^a,b   Melo, T ^a,b   Misra, V ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bioreduction; Gene therapy; Hypoxia; Mechanism; Prodrugs

Indexed keywords

1 (2 BROMOETHYLAMINO) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 2 NITROIMIDAZOLE DERIVATIVE; 3 AMINO 1,2,4 BENZOTRIAZINE; 3 AMINO 1,2,4 BENZOTRIAZINE 1 OXIDE; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ANTHRAQUINONE; MISONIDAZOLE; MITOMYCIN C; NITROFURAN DERIVATIVE; PRODRUG; RADIOSENSITIZING AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TIRAPAZAMINE;

CONFERENCE PAPER; CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; ENZYME ACTIVATION; GASTROINTESTINAL TOXICITY; GENE THERAPY; HYPOXIC CELL; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; RETINOPATHY; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; CELL HYPOXIA; DNA, NEOPLASM; FORECASTING; HUMANS; INDOLEQUINONES; INDOLES; MISONIDAZOLE; MITOMYCIN; NITROFURANS; NITROIMIDAZOLES; OXIDATION-REDUCTION; PRODRUGS; RADIATION-SENSITIZING AGENTS; TRIAZINES;

EID: 0031742631     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00302-2     Document Type: Conference Paper

References (72)

1. Brown J.M. The potential benefit of hypoxic cytotoxins in radio-oncology. Molls M., Vaupel P. Blood perfusion and microenvironment of human tumours, implications for clinical radiooncology. 1998;219-229 Springer-Verlag, Berlin, Heidelberg, New York.
2. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of solid tumours a review . Cancer Res. 49:1989;6449-6465.
3. Coleman C.W., Bump E.A., Kramer R.A. Chemical modifiers of cancer treatment. J Clin Oncol. 6:1988;709-733.
4. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., Giaccia A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (Lond.). 379:1996;88-91.
5. Höckel M., Schlenger K., Mitze M., Schäffer U., Vaupel P. Hypoxia and radiation response in human tumours. Semin Radiat Oncol. 6:1996;3-9.
6. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., Dewhirst M.W. Tumour oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56:1996;941-943.
7. McCalla D.R., Reuvers A., Kaiser C. Mode of action of nitrofurazone. J Bacteriol. 104:1970;1126-1134.
8. Asnis R.E. The reduction of Furacin by cell-free extracts of Furacin-resistant and parent- susceptible strains of Escherichia coli. Arch Biochem Biophys. 66:1957;208-216.
9. Müller M., Lindmark D.G., McLaughlin J. Mode of action of metronidazole on anaerobic microorganisms. Finegold S.M., McFadzean J.A., Roe F.C.C. Metronidazole, proceedings of the International Metronidazole Conference. 1976;12-19 Excerpta Medica, Montreal.
10. Iyer V.N., Szybalski W. Mitomycins and porfiromycins chemical mechanisms of activation and cross-linking of DNA. Science. 145:1964;55-58.
11. Lin A.J., Cosby L.A., Sartorelli A.C. Quinones as anticancer agents Potential bioreductive alkylating agents . Cancer Chem Rep. 4:(part 2):1974;23-25.
12. Adams G.E. Failla Memorial Lecture Redox, radiation and reductive bioactivation . Radiat Res. 132:1992;129-139.
13. Rauth A.M., Kaufman K. In vivo testing of hypoxic radiosensitizers using the KHT murine tumour assayed by the lung-colony technique. Br J Radiol. 48:1975;209-220.
14. Hall E.J., Roizin-Towle L. Hypoxic sensitizers Radiobiological studies at the cellular level . Radiology. 117:1975;453-457.
15. Mohindra J.K., Rauth A.M. Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells. Cancer Res. 36:1976;930-936.
16. Moore B.A., Palcic B., Skarsgard L.D. Radiosensitizing and toxic effects of the 2- nitroimidazole Ro-07-0582 in hypoxic mammalian cells. Radiat Res. 67:1976;459-473.
17. Sutherland R.M. Selective chemotherapy of non-cycling cells in an in vitro tumour model. Cancer Res. 34:1974;3501-3503.
18. McClelland R.A., Panicucci R., Rauth A.M. Products of the reduction of 2- nitroimidazoles. J Am Chem Soc. 109:1987;4308-4313.
19. Farah SF. Aspects of the reduction of 1-methyl-2-nitroimidazole with glutathione and the reaction of 1-methyl-2-nitrosoimidazole with glutathione [Ph.D. thesis].Toronto: University of Toronto, 1990.
20. Noss M.B., Panicucci R., McClelland R.A., Rauth A.M. Preparation, toxicity and mutagenicity of 1-methyl-2-nitrosoimidazole a toxic 2-nitroimidazole reduction product . Biochem Pharmacol. 37:1988;2585-2593.
21. Nunn A., Linder K., Strauss H.W. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med. 22:1995;265-280.
22. Raleigh J.A., Dewhirst M.W., Thrall D.E. Measuring tumour hypoxia. Semin Radiat Oncol. 6:1996;37-45.
23. Rauth A.M., Goldberg Z., Misra V. DT-diaphorase Possible roles in cancer chemotherapy and carcinogenesis . Oncol Res. 9:1997;339-350.
24. Sartorelli A.C., Hodnick W.F., Belcourt M.F., Tomasz M., Haffty B., Fischer J.J., Rockwell S. Mitomycin C a prototype bioreductive agent . Oncol Res. 6:1994;501-508.
25. Zeman E.M., Brown J.M., Lemmon M.J., Hirst V.K., Lee W.W. SR4233 a new bioreductive agent with high selective toxicity for hypoxic mammalian cells . Int J Radiat Oncol Biol Phys. 12:1986;1239-1242.
26. Koch C. Unusual oxygen concentration dependence toxicity of SR-4233, a hypoxic cell toxin. Cancer Res. 53:1993;3992-3997.
27. Elwell J.H., Siim B.G., Evans J.W., Brown J.M. Adaptation of human tumour cells to tirapazamine under aerobic conditions - implications of increased antioxidant enzyme activity to mechanism of aerobic toxicity. Biochem Pharmacol. 54:1997;249-257.
28. Cobb L.M., Connors T.A., Elson L.A., Khan A.H., Mitchley B.C.V., Ross W.C.J., Whisson M.E. 2,4-dinitro-5-ethyleneiminobenzamide (CB1954) a potent and selective inhibitor of the growth of the Walker carcinoma 256 . Biochem Pharmacol. 18:1969;1519-1527.
29. Knox R.J., Friedlos F., Jarman M., Roberts J.J. A new cytotoxic DNA interstrand cross- linking agent, 5-aziridin-1-yl-4-hydroxylamino-2-nitrobenzamide is formed from 5-(azridin-1-yl)-2,4-dinitrobenzamide (CB1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem Pharmacol. 37:1988;4661-4669.
30. Knox R.J., Boland M.P., Friedlos F., Coles B., Southam C., Roberts J.J. The nitroreductase enzyme in Walker cells that activates 5-(azridin-1-yl)-2,4-dinitrobenzamide (CB1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem Pharmacol. 37:1988;4671-4677.
31. Knox R.J., Friedlos F., Boland M.P. The bioactivation of CB1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer Met Rev. 12:1993;195-212.
32. Bridgewater J.A., Knox R.J., Pitts J.D., Collins M.K., Springer C.J. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell permeable metabolite. Human Gene Ther. 8:1997;709-717.
33. Connors T.A., Knox R.J. Prodrugs in cancer chemotherapy. Stem Cells. 13:1995;501-511.
34. Connors T.A. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther. 2:1995;702-709.
35. Knox R.J., Friedlos F., Sherwood R.F., Melton R.G., Anlezark G.M. The bioactivation of 5-(azridin-1-yl)-2,4-dinitrobenzamide (CB1954) - II A comparison of an Escherichia coli nitroreductase and Walker DT-diaphorase . Biochem Pharmacol. 44:1992;2297-2301.
36. Chen S., Knox R., Wu K., Deng P.S.-K., Zhou D., Bianchet M.A., Amzel L.M. Molecular basis of the catalytic differences among DT-diaphorase of human, rat and mouse. (Abstr.) Proc Am Assoc Cancer Res. 38:1997;560, #3756.
37. Stratford I.J., Walling J.M., Silver A.R.J. The differential cytotoxicity of RSU1069 cell survival studies indicating interaction with DNA as a possible mode of action . Br J Cancer. 53:1986;339-344.
38. Bremner J.C.M. Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145 with particular reference to in vivo methods of evaluation . Cancer Met Rev. 12:1993;177-194.
39. Parker R.F., Vincent P.W., Elliot W.L. Alkylating properties of nitro-imidazole radiosenstizers is required for induction of murine retinal degeneration. Vet Pathol. 33:1996;625.
40. Denny W.A., Wilson W.R. Bioreducible mustards a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs) . Cancer Met Rev. 12:1993;135-152.
41. Siim B.G., Denny W.A., Wilson W.R. Nitro reduction as an electronic switch for bioreductive drug activation. Oncol Res. 9:1997;357-369.
42. Skov K.A. Workshop report DNA targeted hypoxic cytotoxins and radiosensitizers . Int J Radiat Biol. 56:1989;387-393.
43. 3)/sensitizer] radiosensitization and toxicity studies in vitro . Radiat Res. 112:1987;273-282.
44. Wilson W.R., Denny W.A., Twigden S.J., Beguley B.C., Probert J.C. Selective toxicity of nitracrine to hypoxic cells. Br J Cancer. 49:1984;215-223.
45. Wilson W.R., Siim B.G., Denny W.A., van Zijl P.L., Taylor M.L., Chambers D.M., Roberts P.B. 5-nitro-4(N,N-dimethylaminopropylamino)quinoline(5-nitroquine), a new DNA affinic hypoxic cell radiosensitizer and bioreductive agent comparison with nitracrine . Radiat Res. 131:1992;257-265.
46. Denny W.A., Roberts P.B., Anderson R.F., Brown J.M., Wilson W.R. NLA-1 a 2- nitroimidazole radiosensitizer targeted to DNA via intercalation . Int J Radiat Oncol Biol Phys. 22:1992;553-556.
47. Cowan D.S.M., Matejovic J.F., McClelland R.A., Rauth A.M. DNA-targeted 2- nitroimidazoles in vitro and in vivo studies . Br J Cancer. 70:1994;1067-1074.
48. Papadapoulou M.V., Ji M., Rao M.K., Bloomer W.D. 9-[3-(2-nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1) A novel DNA-affinic bioreductive agent as chemosensitizer I . Oncol Res. 9:1997;249-257.
49. Patterson L.H. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents a new class of bioreductive agent . Cancer Met Rev. 12:1993;119-134.
50. Smith P.J., Blunt N.J., Desnoyers R., Giles Y., Patterson L.H. DNA topoisomerase II- dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides. Cancer Chemother Pharmacol. 39:1997;455-461.
51. Smitskamp-Wilms E., Hendriks H.R., Peters G.J. Development, pharmacology, role of DT-diaphorase and prospects of the indolquinone EO9. Gen Pharmacol. 27:1996;421-499.
52. Bailey S.M., Wyatt M.D., Friedlos F., Hartley J.A., Knox R.J., Lewis A.D., Workman P. Involvement of DT-diaphorase (EC1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9. Br J Cancer. 76:1997;1596-1603.
53. Boyer M.J. Bioreductive agents A clinical update . Oncol Res. 9:1997;391-395.
54. Flam M., John M., Pajak T.F., Petrelli N., Myerson R., Doggett S., Quivey J., Rotman M., Kerman H., Coia L., Murray K. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal Results of a phase III randomized intergroup study . J Clin Oncol. 14:1996;2527-2539.
55. Haffty B.G., Son Y.H., Papac R., Sasaki C.T., Weissberg J.B., Fischer D., Rockwell S., Sartorelli A.C., Fischer J.J. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck Results of the Yale mitomycin randomized trials . J Clin Oncol. 15:1997;268-276.
56. Connors T.A. Editorial Bioreductive agents, hypoxic cells and therapy . Eur J Cancer. 32A:1996;1833-1834.
57. Stratford I.J. Bioreductive drugs in cancer therapy. Br J Radiol. (Suppl.24):1992;128-136.
58. Bagshawe K.D. Antibody-directed enzyme prodrug therapy (ADEPT). Adv Pharmacol. 24:1993;99-121.
59. Roth J.A., Cristiano R.J. Gene therapy for cancer what have we done and where are we going? J Natl Cancer Inst. 89:1997;21-39.
60. Green N.K., Youngs D.J., Neoptolemos J.P., Friedlos F., Knox R.J., Springer C.J., Anlezpark G.M., Michael N.P., Melton R.G., Ford M.J., Young L.S., Kerr D.J., Searle P.F. Sensitization of colorectal and pancreatic cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther. 4:1997;229-238.
61. Drabek D., Gay J., Craig R., Grosveld F. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954. Gene Ther. 4:1997;93-100.
62. Bailey S.M., Knox R.J., Hobbs S.M., Jenkins T.C., Mauger A.B., Melton R.G., Burke P.J., Connors T.A., Hart I.R. Investigation of alternative prodrugs for use with E. coli nitroreductase in "suicide gene" approaches to cancer therapy. Gene Ther. 3:1996;1143-1150.
63. Friedlos F., Denny W.A., Palmer B.D., Springer C.J. Mustard prodrugs for activation by Escheriahia coli nitroreductase in gene-directed enzyme prodrug therapy. J Med Chem. 40:1997;1270-1275.
64. Cowan D.S.M., Hicks K.O., Wilson W.R. Multicellular membranes as an in vitro model for extravascular diffusion in tumours. Br J Cancer. 74:1996;S28-S31.
65. Hicks K.O., Ohms S.J., van Zijl P.L., Denny W.A., Hunter P.J., Wilson W.R. An experimental and mathematrical model for the extravascular transport of a DNA intercalator in tumours. Br J Cancer. 76:1997;894-903.
66. Minchinton A.I., Wendt K.R., Clow K.A., Fryer K.H. Multilayers of cells growing on a permeable support an in vitro tumour model . Acta Oncol. 36:1997;13-16.
67. Workman P., Stratford I.J. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Met Rev. 12:1993;73-82.
68. Lemmon M.J., van Zijl P., Fox M.E., Mauchline M.L., Giaccia A.J., Minton N.P., Brown J.M. Anaerobic bacteria as a gene delivery system that is controlled by the tumour microenvironment. Gene Ther. 4:1997;791-796.
69. Dachs G.U., Dougherty G.J., Stratford I.J., Chaplin D.J. Targeting gene therapy to cancer a review . Oncol Res. 9:1997;313-326.
70. Dachs G.U., Paterson A.V., Firth J.D., Ratcliffe P.J., Townsend K.M.S., Stratford I.J., Harris A.L. Targeting gene expression to hypoxic tumour cells. Nature Med. 3:1997;515-520.
71. O'Rourke J.F., Dachs G.U., Gleadle J.M., Maxwell P.H., Pugh C.W., Stratford I.J., Wood S.M., Ratcliffe P.J. Hypoxia response elements. Oncol Res. 9:1997;327-332.
72. Freeman S.M., Whartenby K.A., Freeman J.L., Abboud C.N., Marrogi A.J. In situ use of suicide genes for cancer therapy. Semin Oncol. 23:1996;31-45.